Status:
COMPLETED
Differin® Gel x12 Wks vs Tazorac® Cream x12 Wks vs Differin® x6 Wks Switched to Tazorac® x6 Wks for Treatment of Acne
Lead Sponsor:
Galderma R&D
Conditions:
Acne Vulgaris
Eligibility:
All Genders
12-35 years
Phase:
PHASE4
Brief Summary
To determine the efficacy and safety of 12 weeks of treatment with Differin Gel, 0.1% compared to 12 weeks of treatment with Tazorac Cream, 0.1% and compared to 6 weeks treatment with Differin Gel, 0....
Detailed Description
Same as above.
Eligibility Criteria
Inclusion
- Subjects with a minimum of 20 inflammatory lesions (papules and pustules) on the face
- Subjects with a minimum of 15 and a maximum of 100 non-inflammatory lesions (open comedones and closed comedones) on the face, excluding the nose
Exclusion
- Subjects with more than 3 nodulo-cystic lesions
Key Trial Info
Start Date :
February 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2006
Estimated Enrollment :
302 Patients enrolled
Trial Details
Trial ID
NCT00469755
Start Date
February 1 2006
End Date
September 1 2006
Last Update
July 29 2022
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Therapeutics Clinical Research
San Diego, California, United States, 92123
2
Henry Ford Medical Center-Dept. of Dermatology
Detroit, Michigan, United States, 48202
3
Minnesota Clinical Study Center
Fridley, Minnesota, United States, 55432
4
State University of New York Downstate Medical Center-Dept. of Dermatology
Brooklyn, New York, United States, 11203